Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer
暂无分享,去创建一个
G. Sauter | T. Schlomm | S. Steurer | C. Wittmer | R. Simon | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | H. Huland | M. Kluth | C. Hube-Magg | C. Koop | V. Reiswich | Christoph Burdelski | Corinna Wittmer
[1] G. Sauter,et al. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression , 2014, International journal of cancer.
[2] Christian M. Metallo,et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. , 2014, Cancer cell.
[3] G. Sauter,et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers , 2013, Molecular oncology.
[4] A. Partin,et al. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis. , 2013, The Journal of urology.
[5] G. Sauter,et al. High mitochondria content is associated with prostate cancer disease progression , 2013, Molecular Cancer.
[6] H. Okabe,et al. Association of p62/SQSTM1 Excess and Oral Carcinogenesis , 2013, PloS one.
[7] N. Yoo,et al. Alteration of p62/SQSTM1 Expression Is Uncommon in Gastrointestinal and Prostate Cancer Tissues , 2013, Gut and liver.
[8] S. Kurtz,et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.
[9] Jia Fu,et al. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer , 2013, OncoTargets and therapy.
[10] D. Klionsky,et al. Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability. , 2013, Cancer research.
[11] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[12] Jun Yu,et al. FK-16 Derived from the Anticancer Peptide LL-37 Induces Caspase-Independent Apoptosis and Autophagic Cell Death in Colon Cancer Cells , 2013, PloS one.
[13] W. Ding,et al. Role of p62/SQSTM1 in liver physiology and pathogenesis , 2013, Experimental biology and medicine.
[14] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[15] G. Sauter,et al. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers , 2013, Journal of Clinical Pathology.
[16] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[17] A. McEvoy,et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells , 2013, Oncogene.
[18] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[19] I. Thompson,et al. Prostate cancer--uncertainty and a way forward. , 2012, The New England journal of medicine.
[20] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[21] H. Kubo,et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma , 2012, Cancer science.
[22] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[23] Keiji Tanaka,et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells , 2011, The Journal of cell biology.
[24] Y. Eishi,et al. Autophagy-deficient mice develop multiple liver tumors. , 2011, Genes & development.
[25] G. Bhanot,et al. Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2011, Cell.
[26] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[27] Hartwig Huland,et al. Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.
[28] C. Cooper,et al. ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.
[29] Gyan Bhanot,et al. Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2009, Cell.
[30] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[31] J. Flores,et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.
[32] Daniel J. Klionsky,et al. Autophagy fights disease through cellular self-digestion , 2008, Nature.
[33] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[34] N. Sato,et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue , 2006, Histopathology.
[35] M. Glotzer,et al. Cytokinesis: welcome to the Rho zone. , 2005, Trends in cell biology.
[36] G. Bjørkøy,et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death , 2005, The Journal of cell biology.
[37] B. Wold,et al. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells , 2003, Oncogene.
[38] Y. Lee,et al. Immediate early response of the p62 gene encoding a non‐proteasomal multiubiquitin chain binding protein , 1998, FEBS letters.
[39] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[40] T. Visakorpi,et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.
[41] G. Sauter,et al. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy , 2014, Modern Pathology.
[42] P. Auberger,et al. When autophagy meets cancer through p62/SQSTM1. , 2012, American journal of cancer research.
[43] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.